Serological biomarkers have been highly recommended in the screening for early CC due to non-invasive, convenient and safe advantages; nevertheless, current conventional tumor antigen markers (Carcinoembryonic Antigen (CEA), CA19-9 and CA724, etc.)meet a different degree of detection sensitivity or specificity problems, which limit their clinical value for diagnosing CC 4. This evidence concerns the gene CEACAM5 and neoplasm.